SELLAS Life Sciences (SLS) Non-Current Debt (2013 - 2018)
SELLAS Life Sciences (SLS) posted quarterly Non-Current Debt of $1.2 million for Q1 2018, down 55.96% quarter-over-quarter from $2.6 million in Q4 2017.
SELLAS Life Sciences (SLS) Non-Current Debt (2013 - 2018) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Non-Current Debt for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2018.
- In Q1 2018, Non-Current Debt changed N/A year-over-year to $1.2 million; the TTM figure through Mar 2018 stood at $1.2 million (changed N/A YoY), while the FY2017 annual figure was $2.6 million, changed N/A from the prior year.
- Non-Current Debt retreated to $1.2 million in Q1 2018 per SLS's latest filing, from $2.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $6.9 million in Q1 2014 and bottomed at $1.2 million in Q1 2018.
- Historically, Non-Current Debt has averaged $3.8 million across 4 years, with a median of $3.5 million in 2015.
- Annual changes were most pronounced in 2014 — Non-Current Debt tumbled 36.16% — and 2015, when it tumbled 70.06%.
- SELLAS Life Sciences' Non-Current Debt stood at $4.5 million in 2014, then tumbled by 66.03% to $1.5 million in 2015, then soared by 71.1% to $2.6 million in 2017, then sank by 55.96% to $1.2 million in 2018.
- Business Quant data shows SLS's Non-Current Debt at $1.2 million in Q1 2018, $2.6 million in Q4 2017, and $1.5 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 100,000.00 |
| Jun 30, 2018 | 7.80 Mn |
| Mar 31, 2018 | 1.15 Mn |
| Dec 31, 2017 | 2.61 Mn |
| Sep 30, 2015 | 1.53 Mn |
| Jun 30, 2015 | 2.55 Mn |
| Mar 31, 2015 | 3.53 Mn |
| Dec 31, 2014 | 4.49 Mn |
| Sep 30, 2014 | 5.10 Mn |
| Jun 30, 2014 | 6.00 Mn |
| Mar 31, 2014 | 6.88 Mn |
| Dec 31, 2013 | 7.74 Mn |
| Sep 30, 2013 | 8.58 Mn |
| Jun 30, 2013 | 9.40 Mn |